Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness.

Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness.
复制标题

DOI:
10.3390/bioengineering8110155
复制
发表时间:
2021-10-24
期刊:
Bioengineering (Basel, Switzerland)
影响因子:
--
通讯作者:
McHugh KJ
McHugh KJ
中科院分区:
其他
文献类型:
--
作者:
Pogostin BH;McHugh KJ

文献摘要

参考文献

被引文献

相似文献

因此,未来的疾病爆发是不可避免的;尽管我们不知道未来病原体的性质,但我们对这些事件的准备就绪至关重要。在相比的快速设计和生产中,尽管我们对免疫学的理解,但有效的疫苗效率已经大大改善,但较少的疫苗的发展却落后于疫苗,但较少的招聘已经批准了以来,自从发现了第一次调整以来,就已经批准了人类的使用。免疫原性和提高抗原稳定性。
Future infectious disease outbreaks are inevitable; therefore, it is critical that we maximize our readiness for these events by preparing effective public health policies and healthcare innovations. Although we do not know the nature of future pathogens, antigen-agnostic platforms have the potential to be broadly useful in the rapid response to an emerging infection—particularly in the case of vaccines. During the current COVID-19 pandemic, recent advances in mRNA engineering have proven paramount in the rapid design and production of effective vaccines. Comparatively, however, the development of new adjuvants capable of enhancing vaccine efficacy has been lagging. Despite massive improvements in our understanding of immunology, fewer than ten adjuvants have been approved for human use in the century since the discovery of the first adjuvant. Modern adjuvants can improve vaccines against future pathogens by reducing cost, improving antigen immunogenicity, and increasing antigen stability. In this perspective, we survey the current state of adjuvant use, highlight potentially impactful preclinical adjuvants, and propose new measures to accelerate adjuvant safety testing and technology sharing to enable the use of “off-the-shelf” adjuvant platforms for rapid vaccine testing and deployment in the face of future pandemics.
DOI: 10.1586/erv.10.174
发表时间: 2011-04
影响因子: 6.2
作者:
Bode C;Zhao G;Steinhagen F;Kinjo T;Klinman DM
通讯作者: Klinman DM
DOI: 10.3390/vaccines9010065
发表时间: 2021-01-19
期刊: Vaccines
影响因子: 7.8
作者:
Buschmann MD;Carrasco MJ;Alishetty S;Paige M;Alameh MG;Weissman D
通讯作者: Weissman D
DOI: 10.3390/pharmaceutics13010045
发表时间: 2020-12-30
期刊: Pharmaceutics
影响因子: 5.4
作者:
Alfagih IM;Aldosari B;AlQuadeib B;Almurshedi A;Alfagih MM
通讯作者: Alfagih MM
DOI: 10.1002/mnfr.201100715
发表时间: 2012-05-01
影响因子: 5.2
作者:
Chanput, Wasaporn;Reitsma, Marit;Wichers, Harry J.
通讯作者: Wichers, Harry J.
DOI: 10.1021/acs.bioconjchem.7b00656
发表时间: 2018-03-01
影响因子: 4.7
作者:
Dellacherie, Maxence O.;Li, Aileen W.;Mooney, David J.
通讯作者: Mooney, David J.